Statement Of Cash Flows [Abstract]

Biofrontera AG - Filing #6464128

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
4,350 EUR
0 EUR
0 EUR
0 EUR
4,350 EUR
0 EUR
369,000 EUR
0 EUR
369,000 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
1,298 EUR
7,259 EUR
Adjustments for decrease (increase) in inventories
471,000 EUR
283,000 EUR
Adjustments for decrease (increase) in trade accounts receivable
687,000 EUR
5,077 EUR
Adjustments for decrease (increase) in other operating receivables
918,000 EUR
590,000 EUR
Adjustments for increase (decrease) in trade accounts payable
3,278 EUR
711,000 EUR
Adjustments for increase (decrease) in other operating payables
692,000 EUR
2,238 EUR
Adjustments for depreciation and amortisation expense
839,000 EUR
791,000 EUR
Adjustments for provisions
4,359 EUR
305,000 EUR
Other adjustments for non-cash items
21,000 EUR
2,450 EUR
Cash flows from (used in) operating activities
2,539 EUR
1,905 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
210,000 EUR
912,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
3,343 EUR
0 EUR
Payments of lease liabilities, classified as financing activities
464,000 EUR
467,000 EUR
Interest paid, classified as financing activities
53,000 EUR
12,000 EUR
Cash flows from (used in) financing activities
2,793 EUR
479,000 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
44,000 EUR
3,296 EUR
Cash and cash equivalents
3,124 EUR
3,080 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.